Avapritinib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 25 mg, 100 mg, 200 mg
Reference Brands: Ayvakyt (USA/EU)
Category:
Oncology Cancer Care
Avapritinib is a targeted oncology therapy used to treat gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations. It works by inhibiting mutant tyrosine kinases, slowing tumor growth and controlling disease progression. Available as oral capsules in strengths of 25 mg, 100 mg, and 200 mg, Avapritinib is typically administered once daily under specialist supervision.
Avapritinib is available in Capsules
and strengths such as 25 mg, 100 mg, 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Avapritinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Avapritinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing